(This article was created in collaboration with Claude AI)
Key Takeaways:
Brain Imaging Meets Mental Health. Dr. Leanne Williams has developed biotype technology that uses functional MRI to identify distinct subtypes that may underlie biological patterns leading to mental health conditions, moving beyond “one-size-fits-all” diagnoses to personalized treatment approaches.
Seven Years to Seven Weeks. Williams’ precision, personalized psychiatry approach can reduce treatment discovery time from an average of seven years to seven weeks, while improving response rates to over 70%.
Personal Tragedy Fuels Innovation. Williams channeled the loss of her partner to suicide into developing breakthrough technology that identifies the root causes of mental health conditions.
Biotypes Replace Guesswork. Dr. Williams’ Stanford Et Cere brain imaging technology identifies six distinct brain circuits that can point to a higher risk of suicide.
At DOC 2024’s “Advanced Diagnostics and Therapeutics” session, Dr. Leanne Williams opened with a personal story that drove her revolutionary work.
Several years ago, her commitment to precision mental health became personal when her partner, an ER physician who felt too stigmatized to seek treatment, took his own life after years of suffering from depression.
Williams transformed that loss into breakthrough technology, channeling the experience into “a renewed sense of urgency for new solutions.”
Her Stanford Et Cere brain imaging technology represents a shift from traditional psychiatry. Instead of relying on observational diagnoses alone, Williams’ approach takes direct measures of brain function to identify the biological subtypes underlying depression, anxiety, and other conditions. The technology identifies six distinct biotypes recently published in Nature Medicine and Science.
Traditional psychiatry creates one-size-fits-all diagnoses that could lead to months or years of trial-and-error treatments. The statistics are stark: “It takes on average seven years for you or your loved ones to find the right treatment. That’s like waiting for stage 4 cancer.”
Williams’ precision approach can transform those odds. The technology works by taking functional MRI scans — what Williams describes as “a video of your brain in action” — to examine six circuits that regulate cognition. Using biotypes and testing, patients can reach the right treatment within seven weeks while improving response rates to over 70%.
She illustrated her work through a patient of hers, Jane. This pattern carries a fourfold higher risk of suicide. Williams’ team selected a targeted off-label therapy that enhanced the plasticity of Jane’s specific brain circuit. After seven weeks of treatment, Jane’s circuits restored to the healthy range, and she has remained in remission for more than a year.
Now Williams faces the challenge of scale. She’s looking to leverage AI to rapidly expand these biotypes and refine them for other conditions, founding company Et Cere to commercialize the approach. But she needs partners to make the technology widely accessible.
“My ask for today is I would love to find the right investors and clinical partners to scale this approach,” she told the DOC audience.
Williams offers a vision where precision psychiatry may replace guesswork and brain imaging, guiding treatment decisions. Her technology, born from personal loss, points toward a future with a transformed mental healthcare system built on biological understanding rather than trial and error.